Capecitabine Studied In Advanced Colon Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 4
Volume 6
Issue 4

HOUSTON--A new tumor-selective agent may permit delivery of higher levels of 5-fluorouracil (5-FU) with lower toxicity, said Richard Pazdur, MD, of M.D. Anderson Cancer Center. A phase III trial of capecitabine is ongoing in colorectal cancer, and it is also under study for the treatment of breast cancer.

HOUSTON--A new tumor-selective agent may permit delivery of higher levelsof 5-fluorouracil (5-FU) with lower toxicity, said Richard Pazdur, MD,of M.D. Anderson Cancer Center. A phase III trial of capecitabine is ongoingin colorectal cancer, and it is also under study for the treatment of breastcancer.

Capecitabine, which has been developed by Hoffmann-LaRoche, is an oralfluoropyrimidine carbamate that is preferentially converted to 5-FU atthe tumor site, Dr. Pazdur said at the Chemotherapy Foundation Symposium.It undergoes a cascade of conversions from 5´DFCR to 5´-DFURand finally to 5-FU.

Its action depends on the presence of higher levels of pyrimidine nucleosidephosphorylase in tumors than in normal tissue. Taken orally, it passesthrough the intestinal mucosa intact due to its carbamate structure. Itis hoped that this will minimize the diarrhea associated with 5-FU anddoxifluridine (5´-DFUR), which releases 5-FU prodrug within the smallintestine.

The phase III trial is comparing an intermittent capecitabine schedulewith IV dosing of 5-FU and leucovorin in 524 colorectal cancer patients.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Various methods of communication ensure that members from radiation oncology, pathology, and other departments are on the same page regarding treatment.
Related Content